F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 19.36 USD 0.99% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Fortrea Holdings Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fortrea Holdings Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
F
Fortrea Holdings Inc
NASDAQ:FTRE
Cash from Financing Activities
-$139m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Financing Activities
-$4.6B
CAGR 3-Years
-33%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Cash from Financing Activities
-$8.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-34%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Financing Activities
-$881.3m
CAGR 3-Years
-13%
CAGR 5-Years
-12%
CAGR 10-Years
-13%
Agilent Technologies Inc
NYSE:A
Cash from Financing Activities
-$752m
CAGR 3-Years
-3%
CAGR 5-Years
-20%
CAGR 10-Years
-23%
IQVIA Holdings Inc
NYSE:IQV
Cash from Financing Activities
-$923m
CAGR 3-Years
11%
CAGR 5-Years
-59%
CAGR 10-Years
-18%
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.7B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings Inc. operates in the dynamic sphere of Contract Research Organizations (CRO), carving out a niche in the healthcare and biopharmaceutical industries by providing essential services to companies looking to bring new medicinal products and treatments to market. At its core, Fortrea specializes in conducting clinical trials, integrating advanced data analytics, and ensuring regulatory compliance, vital for pharmaceutical firms that often lack the infrastructure to manage these complex processes internally. By offering an array of services—from initial research design through to the final stages of clinical trials—Fortrea positions itself as a critical partner in the drug development lifecycle. This includes preclinical, clinical, and post-approval phases, ensuring that the medicines undergoing testing meet stringent safety and efficacy standards, which is a significant challenge in today's growing demand for faster time-to-market in healthcare innovation. What sets Fortrea apart from many in its industry is its strategic approach to integrating technology with clinical research, leveraging data-driven insights to streamline processes and improve the accuracy of research outcomes. The company generates revenue by entering into contracts with pharmaceutical and biotechnology companies, charging fees for specific research and trial services. Fortrea’s ability to provide tailored solutions that encompass the breadth of clinical services—from design and optimization of clinical studies to statistical analysis and project management—ensures consistent demand for its offerings. In a world where pharmaceutical innovation dictates market share and competitiveness, Fortrea's role in enabling breakthroughs in medical treatments positions it as a cornerstone of the healthcare research community, driving both its relevance and profitability.

FTRE Intrinsic Value
35.3 USD
Undervaluation 45%
Intrinsic Value
Price
F

See Also

What is Fortrea Holdings Inc's Cash from Financing Activities?
Cash from Financing Activities
-139m USD

Based on the financial report for Dec 31, 2023, Fortrea Holdings Inc's Cash from Financing Activities amounts to -139m USD.

What is Fortrea Holdings Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-61%

Over the last year, the Cash from Financing Activities growth was -1 498%. The average annual Cash from Financing Activities growth rates for Fortrea Holdings Inc have been -61% over the past three years .

Back to Top